Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
IL4-H82E0 | Human | Biotinylated Human IL-4 Protein, Avitag™,His Tag | ![]() |
![]() ![]() |
![]() ![]() |
IL4-H4218 | Human | ActiveMax® Human IL-4 Protein, Tag Free | ![]() |
![]() ![]() |
![]() ![]() |
Biotinylated Human IL-4, Avitag,His Tag (Cat. No. IL4-H82E0) stimulates the proliferation of TF-1 human erythroleukemic cells. The ED50 for this effect is 1.19-2.64 ng/mL (Routinely tested).
Immobilized ActiveMax® Human IL-4, Tag Free (Cat. No. IL4-H4218) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-4 R alpha, Avitag,His Tag (Cat. No. ILR-H82E9) with a linear range of 2-78 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Interleukin-4/13 Trap | IL-4/IL-13 trap | Phase Ⅰ | Regeneron Pharmaceutical | Hypersensitivity, Asthma | Details |
GSK-2434735 | GSK-2434735,GSK 2434735,GSK2434735 | Phase Ⅰ | GlaxoSmithKline | Asthma | Details |
AIR-645 | AIR-645; ISIS-369645 | Phase Ⅱ | Ionis, Altair Therapeutics | Allergic asthma | Details |
VAK-694 | VAK-694; NVP-VAK-694 | Phase Ⅱ | Novartis | Seasonal allergic rhinitis | Details |
Pascolizumab | SB-240683 | Phase Ⅱ | GlaxoSmithKline, PDL BioPharma | Asthma | Details |
Binetrakin (Eastman/Immunex) | Phase Ⅱ | Immunex, Eastman | Cancer | Details | |
Dectrekumab/VAK-694 | QBX-258 | Phase Ⅱ | Novartis | Secondary lymphedema, Asthma | Details |
Romilkimab | SAR-156597; SUB-33159 | Phase Ⅱ | Sanofi | Idiopathic pulmonary fibrosis (IPF) | Details |
IL-4R (Aradigm) | Phase Ⅱ | Aradigm | Asthma | Details | |
P-45 | P-45; P-45FP | Phase Ⅱ | IXICO | Alopecia | Details |
OCH-NCNP1 | OCH-NCNP1,OCHNCNP1 | Phase Ⅱ | Keio University, Ajinomoto | Multiple sclerosis (MS), Crohn's disease | Details |
This web search service is supported by Google Inc.